Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T18:18:29.784Z.
Calculation as of: 2026-10-06T18:18:29.784Z.
Quote observation: 2026-10-06T18:15:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64600f38e310d2eb3cd81a0b95bf77f6abd31b9de5548b9cdd3f3c9d46967593
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
PROCEPT BioRobotics Corporation
Market Cap
$986.61M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.18M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.68M
Operating Cash Flow Yield
1.39%
TTM Avg
0.99%
3Y Avg
0.99%
5Y Avg
0.99%
Market Cap
$984.18M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$977.87M
Operating Cash Flow Yield
19.19%
TTM Avg
14.96%
3Y Avg
15.37%
5Y Avg
11.65%
Market Cap
$999.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$969.98M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Operating Cash Flow Yield
6.36%
TTM Avg
6.00%
3Y Avg
6.00%
5Y Avg
6.00%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $986.61M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $987.18M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $987.68M | 1.39% | 0.99% | 0.99% | 0.99% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $984.18M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $977.87M | 19.19% | 14.96% | 15.37% | 11.65% |
| Vor Biopharma Inc. (VOR)vs › | $999.00M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 6.36% | 6.00% | 6.00% | 6.00% |
| Savara Inc. (SVRA)vs › | $954.96M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
